News Article
Given the growing concerns over the COVID-19 (coronavirus) outbreak, the International Myeloma Foundation wants you to know our plans to ensure your access to our resources.
With a focus on the health and well-being of our staff, the IMF’s physical offices will close on Friday, March 13, with a…
News Article
The randomized phase III BOSTON study evaluates “once-weekly XPOVIO® (selinexor) in combination with once-weekly Velcade® (bortezomib) and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd) in patients with multiple myeloma who have received one…
News Article
The International Myeloma Foundation is very pleased that Sarclisa (isatuximab-irfc), a monoclonal antibody that binds to the CD38 receptor on multiple myeloma cells, has just been approved by the FDA.This approval means patients with relapsed/refractory multiple myeloma (RRMM) who have received at…
News Article
The International Myeloma Foundation (IMF) is harnessing the power of multiple myeloma patients, their families, and the community at large to raise awareness of the blood cancer during Myeloma Action Month (MAM), starting March 1, 2020. The organization commemorates its 30-year anniversary this…
Videos
In this week’s video, Dr. Durie discusses what newly diagnosed myeloma patients can expect when it comes to treatment outcomes and the various treatment options available in 2020.
BOTTOM LINE:
In 2020, newly diagnosed patients have a variety of treatment options…
Videos
In this week’s video, Dr. Durie discusses if bone fractures resulting from an accident, such as a fall, could indicate disease progression, and what measures should be taken to find out.
BOTTOM LINE:
Do not rush to treatment before undergoing a full evaluation to assess…
IMF Person
Associate Director, Myeloma Translational Research
The Mount Sinai Health System
New York, NY
IMF Person
With over 7 years of experience in marketing and communications, I am currently leading the development and execution of effective marketing and communications strategies at the International Myeloma Foundation (IMF), a nonprofit organization dedicated to improving the lives of people affected by…
Videos
In this week’s video, Dr. Durie discusses if various infections could trigger onset myeloma.
BOTTOM LINE:
The link between infections and the onset of myeloma is an exciting new area of research.
If you have a question that you’d like to suggest for…
Event
This hour-long workout will begin with a series of seated warm up stretches focusing on the breath. A fusion of standing tai chi patterns and yoga poses will follow. Guided meditation will conclude the workout.
Videos
In this week’s video, Dr. Durie discusses the latest information on the new monoclonal antibody, isatuximab, and how it compares to daratumumab.
BOTTOM LINE:
Isatuximab is a new monoclonal antibody that will likely be approved by the FDA within the year, following…
Videos
In this week’s video, Dr. Durie discusses if Fluorescence in Situ Hybridization (FiSH) testing should be done at relapse.
BOTTOM LINE:
Yes, FiSH testing should be performed at relapse.
Transcript:
This week’s “Ask Dr. Durie” is from a…
News Article
The International Myeloma Foundation announces the launch of a new program created in partnership with Medscape Oncology that offers healthcare professionals an opportunity to earn continuing medical education (CME) credit. "…
Videos
In this week’s video, Dr. Durie discusses how the acquisition of Celgene Corporation by Bristol-Myers Squibb will impact the lives of myeloma patients.
BOTTOM LINE:
The availability of Revlimid and support services for myeloma patients should continue without any…
Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dex in Unfit and Frail NDMM Patients
Videos
Elderly non-transplant eligible newly diagnosed multiple myeloma (nte-NDMM) patients also benefit from novel therapies, however, overall survival (OS) is inferior in unfit and frail compared to fit patients as defined by the International Myeloma Working Group (IMWG) frailty index. This is caused…
News Article
Dr. Durie has written often about the "Blue Zones" that author Dan Buettner noted in his 2005 National Geographic cover article, "Secrets of a Long Life." These Blue Zones are regions of the world where people live much longer than average. Here's what people who live in Blue Zones do—a list of…
Videos
In this week’s video, Dr. Durie discusses if emerging immune therapies such as CAR T cells, and BiTEs, can replace the need for autologous stem cell transplant (ASCT).
BOTTOM LINE:
ASCT treatment is the current standard of care for patients under the age of 65.…
Videos
Daratumumab Plus Bortezomib, Melphalan y Prednisone Versus Bortezomib, Melphalan y Prednisone en pacientes con mieloma múltiple recién diagnosticado no elegible para trasplante: supervivencia general en alcyone
Introduction: Daratumumab (DARA) is a human IgGκ monoclonal…
Videos
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone
Introduction: Daratumumab (DARA) is a human IgGκ monoclonal antibody targeting…
Videos
Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)
…
Videos
Analisi integrativa delle caratteristiche prognostiche di base e raggiungimento della negatività minima della malattia residua come fattori predittivi di recidiva precoce nei pazienti affetti da mieloma multiplo idoneo al trapianto
Background: High rates of response and minimal…
Videos
Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients
Background: High rates of response and minimal residual disease (MRD) negativity have been…
Videos
Εδραίωση με Carfilzomib, Lenalidomide και Dexamethasone (KRd) Μετά από ASCT Αποτελέσματα σε υψηλές τιμές ελάχιστης υπολειμματικής παθολογικής νόσου και βελτιώνει τον μεταβολισμό των οστών, στην απουσία διφωσφονικών, μεταξύ πρόσφατα διαγνωσμένων ασθενών με πολλαπλό μυέλωμα
Consolidation with…
Videos
Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma
Consolidation therapy post…
Videos
Introduction: Proteasome inhibitors (PI), immunomodulatory agents (IMiDs) and the CD38 monoclonal antibody daratumumab (dara) have transformed the management of MM, yet eventual refractoriness to these agents seems inevitable. Relapsed and refractory MM (RRMM) which becomes triple…
Videos
Introduction: JNJ-68284528 (JNJ-4528) is a chimeric antigen receptor T cell (CAR-T) therapy containing two BCMA-targeting single-domain antibodies designed to confer avidity. A first-in-human phase 1 study (LEGEND-2) conducted in China of LCAR-B38M, an identical CAR to JNJ-4528,…
Videos
Introduction: The GEM-CESAR trial is a potentially curative strategy for high-risk smoldering multiple myeloma (HRsMM) patients in which the primary endpoint is the assessment of bone marrow minimal residual disease negativity by next generation flow (NGF). However, alternative…
Videos
Introduction: The GEM-CESAR trial is a potentially curative strategy for high-risk smoldering multiple myeloma (HRsMM) patients in which the primary endpoint is the assessment of bone marrow minimal residual disease negativity by next generation flow (NGF). However, alternative…
Videos
Introduction: Daratumumab, a human IgGκ monoclonal antibody targeting CD38 with a direct on-tumor and immunomodulatory mechanism of action, is approved in combination with standard-of-care regimens for the treatment of newly diagnosed multiple myeloma (NDMM) and RRMM. …
Page
For more than a decade, the International Myeloma Foundation has attended the American Society of Hematology (ASH) annual meeting, an exciting convergence of more than 30,000 health-care professionals from around the world. This year’s ASH annual meeting took place in Orlando, Florida, from Dec. 7-…
Videos
Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple MyelomaBackground: The CD38-…
Videos
Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update
Introduction: DARA, a human IgGκ monoclonal antibody targeting…
Videos
When Is Testing for MRD Applicable and Available?
Myeloma Expert Dr. Brian Durie discusses when testing for minimal residual disease (MRD) is applicable, and the different methods of testing available.
THE BOTTOM LINE:
Outside of clinical trials, MRD testing is not routinely…
Videos
Introduction: Chimeric antigen receptor (CAR) T cell therapy directed against B cell maturation antigen (BCMA) has shown promising results for the treatment of relapsed refractory multiple myeloma (RRMM) in several phase 1 studies. Persistence of CAR T cells post infusion may be…
Videos
fValutazione minima della malattia residua mediante citometria a flusso multiparametrico e sequenziamento di nuova generazione nella sperimentazione Forte per i pazienti affetti da mieloma multiplo di nuova diagnosi
ABOUT FRANCESCA GAY, MD, PhD
Dr. Francesca Gay is a hematologist at the…
Videos
Estrategia curativa (GEM-CESAR) para el mieloma latente de alto riesgo (SMM): Carfilzomib, lenalidomida y Dexametasona (KRd) como inducción Seguido por HDT-ASCT, Consolidación con Krd y Mantenimiento con Rd
Introduction: SMM is an asymptomatic and heterogeneous plasma cell…
Videos
Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients
Background: The role of Minimal residual disease (MRD) as surrogate for survival in Multiple Myeloma (MM)…
Videos
Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd
Introduction: SMM is an asymptomatic and heterogeneous plasma cell…
Videos
LBA-6 Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor
Introduction: The use of…
Videos
Introduction: Denosumab is a monoclonal antibody targeting Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL) that has been shown to reduce skeletal related events associated with bone lesions in patients with multiple myeloma and solid tumors. Results from the full…
Videos
Background: Venetoclax (Ven) is a selective, small molecule inhibitor of anti-apoptosis protein Bcl-2 that has antitumoral activity against multiple myeloma (MM), notably those with translocation t(11;14). Dexamethasone (d) has shown to enhance the expression of BCL-2 and pro-…
Videos
Background: Comorbidities and other patient factors in multiple myeloma (MM) can affect treatment decision making. While chemotherapy selection for MM in Medicare populations is different between blacks and non-blacks, including decreased use of bortezomib (BTZ) and hematopoietic…
Videos
CC-93269, a 2+1 B-cell Maturation Antigen T-cell engager, shows a manageable safety profile and promising efficacy, including MRD-negative stringent complete responses in patients with heavily pretreated relapsed/refractory mulitple myeloma. The study continues to enroll in the dose escalation…
Videos
Dr. Joseph Mikhael presents an overview of the top multiple myeloma research presented at ASH 2019.
ABOUT JOSEPH MIKHAEL, MD
Dr. Joseph Mikhael is a world-renowned multiple myeloma expert. In his position with the IMF, he works closely with the Board Chairman, Dr. Brian G.M. Durie, to…
Videos
In this video, Dr. Rafat Abonour (Indiana University, Indiana) talks about new and promising multiple myeloma clinical trials presented at ASH 2019.
ABOUT RAFAT ABONOUR, MD
Dr. Rafat Abonour holds the title of Professor of Medicine; Professor of Pathology & Laboratory Medicine; Medical…
Videos
click on the image above to watch the webcast
(to view the webcast in fullscreen, click on the bottom right square icon underneath the YouTube logo)
This video is the first in a five-part series that focuses on new strategies for multiple myeloma care. It was presented during the…
Videos
click on the image above to watch the webcast
(to view the webcast in fullscreen, click on the bottom right square icon underneath the YouTube logo)
This video is the third in a five-part series that focuses on new strategies for multiple myeloma care. It was presented during the…
Videos
click on the image above to watch the webcast
(to view the webcast in fullscreen, click on the bottom right square icon underneath the YouTube logo)
This video is the second in a five-part series that focuses on new strategies for multiple myeloma care. It was presented during the…
Videos
click on the image above to watch the webcast
(to view the webcast in fullscreen, click on the bottom right square icon underneath the YouTube logo)
This video is the fourth in a five-part series that focuses on new strategies for multiple myeloma care. It was presented during…